Multiple Sclerosis Disease-Modifying Therapy Access Landscape (2026)

Multiple sclerosis (MS) represents one of the largest and most commercially dynamic specialty neurology therapeutic markets in the United States. With more than 20 FDA-approved disease-modifying therapies (DMTs) spanning injectable, oral, and intravenous biologic modalities, the MS treatment paradigm is defined by a complex interplay between clinical efficacy, generic price erosion, biologic patent cliffs, and payer step-therapy mandates.

Over the past decade, the MS market has undergone two structural shifts. First, the oral DMT tier—once dominated by high-margin brand-name blockbusters like Tecfidera, Gilenya, and Aubagio—has succumbed to multi-source generic competition, driving dramatic retail price reductions visible in National Average Drug Acquisition Cost (NADAC) benchmarks. Second, clinical care has shifted decisively toward high-efficacy biologic agents, primarily anti-CD20 monoclonal antibodies (Ocrevus, Kesimpta, Ocrevus Zunovo) and the anti-alpha-4 integrin natalizumab (Tysabri and its biosimilar Tyruko).

As Genentech/Roche’s market-leading Ocrevus (ocrelizumab) approaches its 2029 U.S. composition-of-matter patent cliff, payers, health systems, and biosimilar developers are positioning for the next wave of biologic price erosion. This decision-grade landscape synthesizes the complete 20+ DMT inventory across three structural tiers, quantifies generic oral price erosion using official FDA Orange Book and CMS NADAC data, evaluates anti-CD20 lifecycle strategies, profiles the biosimilar landscape, and provides a strategic framework for payer formulary sequencing.

---

Executive Summary & Direct Answer

Across all FDA-approved multiple sclerosis disease-modifying therapies, treatment options are structured into three distinct access tiers:

1. Tier 1: Platform Injectables (First-Generation Baseline):

   • Agents: Interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), peginterferon beta-1a (Plegridy), and glatiramer acetate (Copaxone).
   • Access & Pricing Status: Glatiramer acetate is heavily genericized. CMS NADAC pricing benchmarks indicate generic glatiramer 20 mg/mL costs ~$45.37/mL and 40 mg/mL costs ~$101.24/mL. Platform injectables are increasingly relegated to legacy maintenance due to moderate efficacy relative to oral and biologic alternatives.

2. Tier 2: Oral Disease Modifiers (Multi-Source Generic Erosion):

   • Agents: Fumarates (dimethyl fumarate, diroximel fumarate, monomethyl fumarate), S1P receptor modulators (fingolimod, siponimod, ozanimod, ponesimod), pyrimidine synthesis inhibitors (teriflunomide), and purine antimetabolites (cladribine).
   • Access & Pricing Status: The first-wave oral blockbusters have experienced multi-source generic entry. According to the FDA Orange Book (July 2026 export), dimethyl fumarate (Tecfidera) has 17 approved generic ANDAs, fingolimod (Gilenya) has 19 ANDAs, and teriflunomide (Aubagio) has 19 ANDAs. NADAC data shows dimethyl fumarate 120 mg delayed-release capsules priced at ~$0.94/capsule ($0.52 for 240 mg), and generic fingolimod 0.5 mg capsules at ~$5.33/capsule. Branded S1P modulators (Mayzent, Zeposia, Ponvory) and Mavenclad retain brand pharmacy benefit coverage with prior authorization.

3. Tier 3: High-Efficacy Biologics & Biosimilars (Medical Benefit Focus):

   • Anti-CD20 Monoclonal Antibodies: Ocrevus (ocrelizumab IV, FDA approved Mar 28, 2017), Ocrevus Zunovo (ocrelizumab + hyaluronidase-ocsq SC, FDA approved Sep 13, 2024), and Kesimpta (ofatumumab SC self-injection, FDA approved Aug 20, 2020).
   • Anti-Alpha-4 Integrin: Tysabri (natalizumab IV, FDA approved Nov 23, 2004) and Tyruko (natalizumab-sztn, Sandoz, FDA approved Aug 24, 2023 as the first 351(k) natalizumab biosimilar).
   • Access & Pricing Status: Biologic DMTs are buy-and-bill or specialty medical benefit drugs ($40,000–$75,000+ annual WAC). Because they pass through medical benefit claims rather than retail pharmacies, biologic DMTs are virtually absent from retail NADAC pricing. Ocrevus faces a major 2029 U.S. composition-of-matter patent cliff; Roche’s attempt to extend exclusivity via a high-dose IV Ocrevus formulation failed in Phase 3 trials in 2024, heightening biosimilar vulnerability.

---

The 3-Tier Multiple Sclerosis DMT Access Landscape

To provide a complete decision framework, the table below consolidates the FDA-approved MS DMT landscape across modality tiers, approval status, generic/biosimilar availability, and primary reimbursement channels:

For deeper operational analysis on how anti-CD20 subcutaneous lifecycle extensions alter HCP billing dynamics, consult our detailed comparison of Ocrevus Zunovo vs Ocrevus IV coverage.

---

Detailed Mechanism of Action and Immunological Targets

Understanding the immunological targets across MS DMT tiers is essential for evaluating clinical sequencing, safety monitoring, and prior authorization documentation.

1. Platform Injectables (Interferons & Glatiramer Acetate)

• Interferon beta-1a / beta-1b: Modulates anti-inflammatory and pro-inflammatory cytokine secretion, suppresses autoreactive T-cell proliferation, and enhances blood-brain barrier integrity. However, neutralizing antibodies (NAbs) develop in a subset of patients, leading to secondary loss of efficacy.
• Glatiramer Acetate: A random polymer of four amino acids (L-glutamic acid, L-alanine, L-lysine, and L-tyrosine) designed to mimic myelin basic protein (MBP). It acts as a decoy antigen, shifting the immune response from pro-inflammatory Th1/Th17 phenotypes to regulatory Th2 cells that cross into the central nervous system to suppress local inflammation.

2. Oral Disease Modifiers (Fumarates, S1P Modulators, Teriflunomide, Cladribine)

• Fumarate Derivatives (Dimethyl Fumarate, Diroximel Fumarate): Activates the Nuclear factor erythroid 2-related factor 2 (Nrf2) transcriptional pathway, protecting oligodendrocytes and neurons from oxidative stress while promoting cytoprotective cellular responses.
• Sphingosine-1-Phosphate (S1P) Receptor Modulators (Fingolimod, Siponimod, Ozanimod, Ponesimod): Binds to S1P1 receptors on lymphocytes, causing receptor internalisation. This sequesters autoreactive T- and B-lymphocytes within lymph nodes, preventing their migration into the central nervous system. Subtype-selective agents (siponimod for S1P1/S1P5, ozanimod for S1P1/S1P5) aim to minimize cardiac conduction abnormalities associated with unselective S1P3 binding.
• Teriflunomide: Reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), blocking de novo pyrimidine synthesis in rapidly proliferating activated lymphocytes while sparing resting cells that rely on salvage pathways.
• Cladribine: A purine nucleoside analog that undergoes selective intracellular phosphorylation in lymphocytes, causing double-strand DNA breaks and transient depletion of T- and B-cells, followed by immune reconstitution.

3. High-Efficacy Biologics (Anti-CD20 Monoclonal Antibodies & Integrin Blockers)

• Anti-CD20 Monoclonal Antibodies (Ocrelizumab, Ofatumumab): Binds to the CD20 cell surface antigen expressed on pre-B cells, mature B-cells, and memory B-cells (sparing hematopoietic stem cells and plasma cells). Depletion occurs via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), removing B-cells responsible for antigen presentation, autoantibody production, and pro-inflammatory cytokine secretion.
• Anti-Alpha-4 Integrin (Natalizumab): Monoclonal antibody targeting the $\alpha4\beta1$ integrin (VLA-4) expressed on leukocyte surfaces. By blocking the interaction between VLA-4 and vascular cell adhesion molecule-1 (VCAM-1) on cerebral vascular endothelial cells, natalizumab prevents transmigration of mononuclear leukocytes across the blood-brain barrier into the CNS parenchyma.

---

Generic Oral Erosion: Orange Book ANDAs and NADAC Price Collapse

The loss of patent exclusivity for first-generation oral DMTs transformed MS market dynamics. Between 2020 and 2023, generic entry for Tecfidera (dimethyl fumarate), Gilenya (fingolimod), and Aubagio (teriflunomide) eroded billions in branded revenue and established a low-cost oral tier that payers now utilize as a primary step-therapy gatekeeper.

                  GENERIC ORAL DMT ANDA COUNT & PRICE EROSION
                  -------------------------------------------
  Agent (Brand)         Orange Book ANDA Count   NADAC Benchmark Price (2025/2026)
  ---------------------------------------------------------------------------------
  Dimethyl Fumarate     [=================] 17   ~$0.94 / 120mg cap ($0.52 / 240mg)
  (Tecfidera)
  ---------------------------------------------------------------------------------
  Fingolimod HCl        [===================] 19 ~$5.33 / 0.5mg cap
  (Gilenya)
  ---------------------------------------------------------------------------------
  Teriflunomide         [===================] 19 Price eroded >92% from WAC
  (Aubagio)

1. Orange Book ANDA Quantification

Data extracted from the FDA Orange Book (July 2026 export) demonstrates extraordinary generic crowding in the oral MS space:

• Dimethyl Fumarate: 17 approved Abbreviated New Drug Applications (ANDAs) across manufacturers including Mylan, Glenmark, Lupin, Alvogen, and Zydus.
• Fingolimod Hydrochloride: 19 approved generic ANDAs following the resolution of section 112 patent litigation.
• Teriflunomide: 19 approved generic ANDAs.

2. CMS NADAC Price Benchmark Collapse

According to CMS National Average Drug Acquisition Cost (NADAC) data:

• Dimethyl Fumarate: The 120 mg delayed-release capsule maintains a NADAC of ~$0.94 per capsule, while the 240 mg maintenance capsule sits at ~$0.52 per capsule. Compared to Tecfidera’s peak branded WAC of over $7,000 per month (~$116 per capsule), generic entry delivered a >99% drop in acquisition cost.
• Fingolimod: Generic 0.5 mg capsules carry a NADAC of ~$5.33 per capsule (~$160 per month), down from Gilenya’s peak branded WAC of ~$8,400 per month.
• Glatiramer Acetate: Generic 20 mg/mL prefilled syringes carry a NADAC of ~$45.37 per mL, while the 40 mg/mL formulation costs ~$101.24 per mL.

This multi-source generic crowding has established a "generic oral baseline" that health plan P&T committees enforce prior to approving branded oral S1P modulators (Mayzent, Zeposia, Ponvory) or high-cost biologics.

---

The Ocrevus 2029 Biologic Cliff & Anti-CD20 Lifecycle Battles

Genentech/Roche’s Ocrevus (ocrelizumab) is the dominant therapeutic entity in multiple sclerosis, generating over $7 billion in global annual sales. As a humanized anti-CD20 monoclonal antibody administered as a twice-yearly IV infusion, Ocrevus captured over 40% of the total MS market by establishing superior efficacy in relapsing MS (RMS) and becoming the first FDA-approved treatment for primary progressive MS (PPMS).

                      OCREVUS EXCLUSIVITY & LIFECYCLE TIMELINE
                      ----------------------------------------
   2017 Mar  : FDA approves Ocrevus IV (BLA 761053) for RMS and PPMS
   2020 Aug  : Novartis launches Kesimpta SC (ofatumumab) self-injection competitor
   2024 Sep  : FDA approves Ocrevus Zunovo SC (ocrelizumab + hyaluronidase)
   2024 Oct  : Roche announces Phase 3 trial FAILURE for High-Dose Ocrevus IV
   2029      : U.S. Composition-of-Matter Patent Expiry (THE BIOLOGIC CLIFF)
   2029-2030 : Anticipated 351(k) Biosimilar Ocrelizumab Market Launches

1. The 2029 Composition-of-Matter Expiry

The core U.S. composition-of-matter patent protecting ocrelizumab is scheduled to expire in 2029. Unlike small-molecule drugs that face rapid multi-source ANDA erosion, biologics face competition from 351(k) biosimilars. However, given Ocrevus's massive revenue base, major biosimilar developers (including Sandoz, Celltrion, Samsung Bioepis, and Biocon) have active ocrelizumab biosimilar programs in Phase 3 comparative analytical and clinical trials.

2. The Failed High-Dose Lifecycle Defense

To defend its anti-CD20 franchise against impending 2029 biosimilar erosion, Roche initiated Phase 3 clinical trials evaluating a high-dose Ocrevus IV formulation (1,200 mg, double the standard dose), hypothesizing that deeper B-cell depletion in central nervous system compartments would slow disability progression in RMS and PPMS. However, in late 2024, Roche announced that the Phase 3 high-dose trial failed to meet its primary endpoint, failing to demonstrate a statistically significant reduction in 24-week confirmed disability progression over the standard dose.

This Phase 3 clinical setback leaves Roche relying entirely on Ocrevus Zunovo—the subcutaneous co-formulation with Halozyme’s ENHANZE drug delivery technology (hyaluronidase-ocsq) approved on September 13, 2024—to transition patients away from IV infusion centers before 2029.

3. Anti-CD20 Head-to-Head Comparison

The anti-CD20 class is split between three distinct delivery paradigms:

ANTI-CD20 DELIVERY & REIMBURSEMENT MATRIX
----------------------------------------------------------------------------------
Parameter            Ocrevus IV             Ocrevus Zunovo SC     Kesimpta SC
----------------------------------------------------------------------------------
Active Molecule      Ocrelizumab            Ocrelizumab +         Ofatumumab
                                            Hyaluronidase
Sponsor              Genentech / Roche      Genentech / Roche     Novartis
Administration       IV Infusion            10-Minute SC          Monthly SC
                     (Bi-annual)            Infusion (Bi-annual)  Self-Injection
Site of Care         Hospital / Infusion    HCP Office /          Home Self-Admin
                     Center                 Infusion Suite        (Auto-injector)
Benefit Channel      Medical Benefit        Medical Benefit       Pharmacy Benefit
                     (Buy-and-Bill, J2350)  (HCP Billing, J2351)  (Specialty Mail)
----------------------------------------------------------------------------------

For specific prior authorization mechanics on Novartis's self-injected anti-CD20, see our guide on Kesimpta (ofatumumab) coverage.

---

The Biosimilar Frontier: Tyruko and Pipeline Anti-CD20s

While the oral DMT tier experienced generic erosion via small-molecule ANDAs, the biologic DMT tier is entering the biosimilar era under the Public Health Service Act 351(k) pathway.

1. Tyruko (Natalizumab-sztn): The First MS Biosimilar

On August 24, 2023, the FDA approved Sandoz’s Tyruko (natalizumab-sztn) as the first biosimilar to Biogen’s Tysabri (natalizumab) for all approved indications in relapsing forms of MS and Crohn’s disease.

• Regulatory Status: Licensed under BLA 761307 as a 351(k) biosimilar. Demonstrates no clinically meaningful differences in safety, purity, or potency from reference Tysabri.
• REMS Requirement: Because natalizumab carries a risk of Progressive Multifocal Leukoencephalopathy (PML) caused by John Cunningham virus (JCV) reactivation, Tyruko was approved with a single shared system Risk Evaluation and Mitigation Strategy (REMS)—the Tyruko REMS program—mirroring the established Tysabri TOUCH REMS protocol.
• Commercial & Payer Uptake: Tyruko adoption has been gradual due to complex REMS prescriber recertification, mandatory pre-infusion anti-JCV antibody testing, and Biogen’s contracting tactics (offering bundled rebates across its MS portfolio to protect Tysabri formulary position).

2. Pipeline Biosimilars Approaching 2029

Following Tyruko's precedent, biosimilar development is concentrated on anti-CD20 targets. Multiple 351(k) biosimilar candidates for ocrelizumab are in Phase 3 development:

• Celltrion (CT-P53): Active Phase 3 comparative clinical trial in relapsing-remitting MS.
• Samsung Bioepis (SB23): Phase 3 trial assessing pharmacokinetic equivalence and clinical efficacy.
• Sandoz / Polpharma: Advanced preclinical and analytical matching for ocrelizumab biosimilars.

---

Payer Step-Therapy Protocols and Formulary Sequencing

Payer coverage for MS DMTs is governed by strict step-therapy protocols, site-of-care restrictions, and benefit-channel routing. Because MS care requires long-term disease management, payers balance immediate drug acquisition costs against long-term disability progression costs.

                         TYPICAL PAYER STEP-THERAPY SEQUENCING
                                          |
                 +------------------------+------------------------+
                 |                                                 |
         TRADITIONAL STEP-THERAPY                               HIGH-EFFICACY EARLY INTERVENTION
         (Escalation Model)                                     (Modern Clinical Model)
                 |                                                 |
   Step 1: Generic Oral (DMF, Fingolimod,               First-Line Access to Anti-CD20
           or Teriflunomide)                            (Ocrevus IV / Zunovo, Kesimpta)
                 |                                                 |
   Step 2: Branded Oral S1P or                          Requires PA Documentation:
           Platform Injectable                          - Highly active disease (MRI lesions)
                 |                                      - Poor prognostic factors
   Step 3: High-Efficacy Biologic                       - Rapid relapse rate
           (Ocrevus, Kesimpta, Tysabri)

1. Traditional Escalation vs. Early High-Efficacy Therapy

Historically, payers enforced an escalation model: requiring patients to start on low-cost Tier 1 platform injectables or Tier 2 generic oral agents, stepping up to high-efficacy Tier 3 biologics only after documented clinical failure (new MRI contrast-enhancing lesions or clinical relapses).

However, modern neuro-immunological consensus strongly favors early high-efficacy therapy (initiating anti-CD20s or natalizumab at diagnosis) to prevent irreversible axonal loss and long-term disability accumulation. In response, health plans have updated prior authorization criteria:

• Fast-Track Prior Authorization: Patients presenting with "highly active" relapsing MS (defined as $\ge 2$ relapses in the preceding 12 months, or high lesion burden on brain/spine MRI) qualify for immediate first-line anti-CD20 coverage without requiring step-therapy through generic oral drugs.
• JCV Risk Stratification for Natalizumab: Tysabri and Tyruko coverage requires mandatory anti-JCV antibody index testing. Patients testing JCV-negative qualify for first-line coverage; patients testing JCV-positive ($\text{index} > 0.9$) are systematically routed away from natalizumab to anti-CD20 agents to eliminate PML risk.

2. Benefit Channel & Site-of-Care Controls

Payers aggressively manage the administrative split between the Pharmacy Benefit and Medical Benefit:

• Pharmacy Benefit (Self-Administered): Oral generics (dimethyl fumarate, fingolimod), oral brands (Mayzent, Mavenclad), and self-injected Kesimpta pass through retail/specialty mail order pharmacies. Payers utilize pharmacy benefit managers (PBMs) to enforce copay accumulators, specialty tiers, and split-fill protocols.
• Medical Benefit (Buy-and-Bill Infusions): Ocrevus IV, Ocrevus Zunovo, Tysabri, and Tyruko are reimbursed under medical benefit claims using HCPCS J-codes (J2350 for Ocrevus, J2323 for Tysabri, Q5134 for Tyruko). Payers increasingly mandate site-of-care edits, redirecting infusions away from high-cost hospital outpatient departments (HOPDs) to independent infusion suites or home infusion providers.

3. Copay Accumulator and Maximizer Impact

For self-administered oral and subcutaneous MS therapies billed through the pharmacy benefit, PBM copay accumulator adjustment programs (CAAPs) prevent manufacturer copay assistance cards from counting toward patient annual out-of-pocket maximums. Patients facing high deductible tiers may experience mid-year prescription abandonment when copay assistance funds are exhausted. Consequently, specialty pharmacy hubs play an essential role in navigating copay maximizers and foundation grants for eligible MS patients.

For broader analysis of how health plans apply site-of-care edits to intravenous and subcutaneous specialty drugs, see our report on IV-to-subcutaneous site-of-care edits. For cross-specialty formulary comparisons in adjacent neuro-inflammatory markets, see 2026 readouts and formulary access.

---

Safety & Signal Surveillance: FAERS MS-DMT Data

Postmarket safety monitoring remains a critical component of MS therapy management, particularly regarding opportunistic infections, lymphopenia, and secondary autoimmunity. In the openFDA FAERS database (data export through mid-2026), adverse event reporting for MS DMTs reflects distinct safety profiles across drug classes:

FAERS Reporting Volume Across Selected MS DMT Classes
----------------------------------------------------------------------------------
Therapy Class         Representative Agents   Primary FAERS Safety Signals
----------------------------------------------------------------------------------
Anti-CD20 Biologics   Ocrevus, Kesimpta       Infusion reactions, upper respiratory
                                              infections, hypogammaglobulinemia
----------------------------------------------------------------------------------
Integrin Inhibitors   Tysabri, Tyruko         Progressive Multifocal Leukoencephalopathy
                                              (PML / JCV reactivation), hypersensitivity
----------------------------------------------------------------------------------
S1P Modulators        Gilenya, Mayzent        Bradycardia, macular edema, PML,
                                              rebound disease upon discontinuation
----------------------------------------------------------------------------------
Fumarates             Tecfidera, Vumerity     Flushing, GI events, lymphopenia,
                                              rare PML (severe prolonged lymphopenia)
----------------------------------------------------------------------------------

For detailed quantitative breakdowns of FAERS adverse event counts across individual MS DMT molecules and reporting years, consult our companion data brief on multiple sclerosis DMT adverse events by the numbers.

---

Frequently Asked Questions (FAQ)

What is the difference between Ocrevus, Ocrevus Zunovo, and Kesimpta?

All three are anti-CD20 monoclonal antibodies that deplete B-cells to treat relapsing multiple sclerosis. Ocrevus is an IV infusion administered in a health care facility twice yearly. Ocrevus Zunovo is a subcutaneous formulation of ocrelizumab co-formulated with hyaluronidase, administered by a healthcare professional twice yearly as a 10-minute injection. Kesimpta (ofatumumab) is a subcutaneous self-injection administered monthly at home by the patient using an autopen.

Are Tecfidera, Gilenya, and Aubagio available as generics?

Yes, all three first-generation oral DMTs have faced multi-source generic entry in the United States. The FDA Orange Book lists 17 approved generic ANDAs for dimethyl fumarate (Tecfidera), 19 ANDAs for fingolimod (Gilenya), and 19 ANDAs for teriflunomide (Aubagio), resulting in significant retail price reductions reflected in CMS NADAC benchmarks.

Is there a biosimilar to Ocrevus or Tysabri, and when?

Tysabri (natalizumab) has an FDA-approved biosimilar: Tyruko (natalizumab-sztn), approved by the FDA on August 24, 2023. Ocrevus (ocrelizumab) does not yet have an approved biosimilar; its core U.S. composition-of-matter patent expires in 2029, and multiple 351(k) biosimilars (from Celltrion, Samsung Bioepis, and Sandoz) are currently in Phase 3 clinical trials ahead of anticipated 2029–2030 launches.

Why are biologic MS DMTs absent from retail pharmacy pricing (NADAC)?

Retail pharmacy benchmarks like CMS NADAC reflect acquisition costs paid by retail community pharmacies for self-administered oral and injectable drugs. Biologic MS DMTs such as Ocrevus, Ocrevus Zunovo, Tysabri, and Tyruko are administered in clinical settings and billed through the Medical Benefit via buy-and-bill or specialty infusion providers (using HCPCS J-codes), excluding them from retail pharmacy NADAC surveys.

---

Sources

1. U.S. Food and Drug Administration (FDA): Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Dataset search for Dimethyl Fumarate, Fingolimod, and Teriflunomide ANDAs (July 2026 export). https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. Food and Drug Administration (FDA): Purple Book: Database of Licensed Biological Products. Search for Ocrevus (BLA 761053), Ocrevus Zunovo (BLA 761338), Kesimpta (BLA 125326), Tysabri (BLA 125104), and Tyruko (BLA 761307). https://purplebooksearch.fda.gov/
3. Centers for Medicare & Medicaid Services (CMS): National Average Drug Acquisition Cost (NADAC) Database. Weekly files (July 2026 pricing benchmarks for generic oral DMTs and glatiramer). https://www.cms.gov/medicare/prescription-drug-coverage/pharmacy/nadac-pricing-files
4. PatSnap Eureka Life Science: Ocrelizumab Competitive Patent & Exclusivity Landscape Analysis (2029 U.S. Composition-of-Matter Expiry). https://eureka.patsnap.com/blog/life-science/ocrelizumab-competitive-landscape-analysis/
5. Fierce Pharma: Roche Hits Setback as High-Dose Ocrevus Phase 3 Trial Fails to Meet Primary Endpoint Ahead of Looming Biosimilar Threat. Trade Press Report. https://www.fiercepharma.com/pharma/biosimilar-competition-looming-roche-takes-hit-failure-high-dose-ocrevus
6. U.S. Food and Drug Administration (FDA): FDA Approves First Biosimilar to Tysabri (Tyruko / natalizumab-sztn). FDA Press Release, Aug 24, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-tysabri-treatment-relapsing-forms-multiple-sclerosis
7. Multiple Sclerosis International Federation (MSIF): DMT Patent and Generic/Biosimilar Exclusivity Map. https://www.msif.org/